Tracking a skin disease treatment in real patients
NCT ID NCT07282015
Summary
This study aims to see how well the drug secukinumab works for people with moderate-to-severe hidradenitis suppurativa (HS) in real-world Canadian clinics. It will follow 142 adult patients newly prescribed this medication to track changes in their disease severity, side effects, and treatment patterns over 12 months. The goal is to understand the real-life benefits and safety of this treatment option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGWinnipeg, Manitoba, R3M 3Z4, Canada
-
Novartis Investigative Site
RECRUITINGHamilton, Ontario, L8P4B4, Canada
-
Novartis Investigative Site
RECRUITINGMarkham, Ontario, L3P 1X3, Canada
-
Novartis Investigative Site
RECRUITINGMississauga, Ontario, L4W 0C2, Canada
-
Novartis Investigative Site
RECRUITINGRichmond Hill, Ontario, L4C 9M7, Canada
-
Novartis Investigative Site
RECRUITINGWaterloo, Ontario, N2J 1C4, Canada
-
Novartis Investigative Site
RECRUITINGSherbrooke, Quebec, J1L 0H8, Canada
Conditions
Explore the condition pages connected to this study.